Advanced BioScience Laboratories Inc (ABL) is a biotech company that provides contract manufacturing and laboratory research services for vaccines and therapies from clinical development to the commercial market. The company’s current good manufacturing practice (cGMP) facilities offer development and manufacturing support for protein and virus production using single-use bioreactor platforms and other disposable technologies. ABL provides clients with an integrated solution that includes cell line and process development, GMP manufacturing, quality control (QC) release testing, and quality assurance (QA)/regulatory support. ABL works with clients to design and run immunogenicity studies, biomarker analyses, and other evaluations to understand the impact of cutting-edge therapies, the mechanism of action, and correlates protection, pharmacokinetic/pharmacodynamics studies, and other critical safety and efficacy data. The company carries out production and testing of oncolytic viruses, gene therapies, immunotherapies, viral vaccines, and recombinant protein vaccines. ABL’s contract research teams provide expertise in immunoassays, developing custom assays, and panels to support human clinical trials and preclinical animal studies. ABL’s cell-based assays include custom assay development, immunophenotyping, intracellular cytokine staining (ICS), tetramer and multimer staining, and lymphoproliferation study; immunoassay testing covers anti-drug antibodies (ADA), antibody affinity measurement, complement dependent cell cytotoxicity (CDC), and epitope mapping; and biomarker and cytokine detection, which consist of ultra-sensitive and multiplexed assays, cytokines, chemokines, and neurological biomarkers.